Medicare Enrolled

Dr. Amirhassan Bahreman, M.D.

Neurology · La Mesa, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
8851 CENTER DR, La Mesa, CA 91942
6194605850
In practice since 2005 (20 years)
NPI: 1164426953 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bahreman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bahreman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bahreman

Dr. Amirhassan Bahreman is a neurology specialist in La Mesa, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bahreman performed 1,577 Medicare services across 1,139 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bahreman received a total of $16,997 from 70 pharmaceutical and/or device companies across 764 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bahreman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 23% volume in CA $16,997 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,577
Medicare services
Top 23% in CA for neurology
1,139
Unique beneficiaries
$158
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~79 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
444 $146 $596
Electromyography of arm or leg muscles
A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them.
438 $87 $600
Nerve conduction studies, 13 or more
A diagnostic test that measures how well nerves send electrical signals. This code applies when 13 or more individual nerve studies are performed.
219 $249 $1,200
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
149 $134 $220
New patient office visit, complex (60-74 min) 128 $182 $1,268
Awake and drowsy EEG
A test that records electrical activity in the brain while the patient is awake and drowsy.
113 $350 $1,600
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
73 $109 $170
Autonomic nervous system function test
This test evaluates how well the sympathetic nervous system is functioning. It assesses the automatic control of bodily processes such as heart rate and blood pressure.
13 $111 $350
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$16,997
Total received (2018-2024)
Avg $2,428/year across 7 years
Top 17% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
764
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,662 (98.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$335 (2.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,165
2023
$2,808
2022
$2,389
2021
$2,149
2020
$1,694
2019
$1,901
2018
$1,891

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$926
Alexion Pharmaceuticals, Inc.
$365
Lilly USA, LLC
$287
TG Therapeutics, Inc.
$286
SK Life Science, Inc.
$283
MDD US Operations, LLC
$219
Eisai Inc.
$198
ABBVIE INC.
$171
ACADIA Pharmaceuticals Inc
$143
Neurocrine Biosciences, Inc.
$131
AstraZeneca Pharmaceuticals LP
$121
Alnylam Pharmaceuticals Inc.
$96
Lundbeck LLC
$92
Neurelis, Inc.
$84
Teva Pharmaceuticals USA, Inc.
$84
PFIZER INC.
$82
Kyowa Kirin, Inc.
$79
MITSUBISHI TANABE PHARMA AMERICA, INC.
$75
Amneal Pharmaceuticals LLC
$72
Biogen, Inc.
$70
Grifols USA, LLC
$68
Genentech USA, Inc.
$66
Sumitomo Pharma America, Inc.
$46
Curonix LLC
$35
GlaxoSmithKline, LLC.
$32
InSightec,Inc
$21
Abbott Laboratories
$18
SCILEX PHARMACEUTICALS INC.
$14
Top 3 companies account for 37.9% of 2024 payments
All-time payments by company (2018-2024) ›
UCB, Inc.
$2,005
Biogen, Inc.
$1,451
Teva Pharmaceuticals USA, Inc.
$934
Sunovion Pharmaceuticals Inc.
$896
Neurocrine Biosciences, Inc.
$646
Alexion Pharmaceuticals, Inc.
$602
Eisai Inc.
$587
CSL Behring
$493
SK Life Science, Inc.
$481
ACADIA Pharmaceuticals Inc
$445
Lilly USA, LLC
$440
Adamas Pharmaceuticals, Inc.
$367
ABBVIE INC.
$355
Acorda Therapeutics, Inc
$351
AbbVie Inc.
$312
Genentech USA, Inc.
$309
Abbott Laboratories
$307
Vanda Pharmaceuticals Inc.
$288
TG Therapeutics, Inc.
$286
Janssen Pharmaceuticals, Inc
$264
Alnylam Pharmaceuticals Inc.
$261
MDD US Operations, LLC
$244
GE HEALTHCARE
$241
Kyowa Kirin, Inc.
$236
Supernus Pharmaceuticals, Inc.
$226
Allergan, Inc.
$225
Grifols USA, LLC
$218
Amneal Pharmaceuticals LLC
$216
AstraZeneca Pharmaceuticals LP
$211
Neurelis, Inc.
$200
Nevro Corp.
$200
Lundbeck LLC
$199
ARGENX US, INC.
$190
Biohaven Pharmaceutical Holding Company Ltd.
$186
EISAI INC.
$174
GE HealthCare
$171
PFIZER INC.
$170
Akcea Therapeutics, Inc.
$156
GE Healthcare
$149
Sumitomo Pharma America, Inc.
$148
GENZYME CORPORATION
$125
Takeda Pharmaceuticals U.S.A., Inc.
$114
MITSUBISHI TANABE PHARMA AMERICA, INC.
$75
Vertical Pharmaceuticals, LLC
$71
CATALYST PHARMACEUTICALS, INC.
$69
Dynasplint Systems Inc.
$65
Biohaven Pharmaceuticals, Inc.
$55
Banner Life Sciences, LLC
$50
Amgen Inc.
$46
LivaNova USA, Inc.
$43
Curonix LLC
$35
Avanir Pharmaceuticals, Inc.
$35
GlaxoSmithKline, LLC.
$32
Medtronic, Inc.
$30
Azurity Pharmaceuticals, Inc.
$29
TG THERAPEUTICS, INC.
$26
BOSTON SCIENTIFIC CORPORATION
$24
Boston Scientific Corporation
$23
Avion Pharmaceuticals
$22
Novartis Pharmaceuticals Corporation
$22
InSightec,Inc
$21
Chiesi USA, Inc.
$21
Assertio Therapeutics, Inc.
$20
Mylan Pharmaceuticals Inc.
$19
ASSERTIO THERAPEUTICS, INC.
$16
BANNER LIFE SCIENCES, LLC
$16
SCILEX PHARMACEUTICALS INC.
$14
Arbor Pharmaceuticals, Inc.
$14
Allergan Inc.
$12
Bayer HealthCare Pharmaceuticals Inc.
$12
Top 3 companies account for 25.8% of all-time payments
Associated products mentioned in payments ›
ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMVUTTRA · AMYVID · APTIOM · AREXVY · AUBAGIO · AUSTEDO · Aimovig · Austedo XR · BAFIERTAM · BOTOX · BRILINTA · BRIUMVI · Banzel · Betaseron · Briviact · CLEVIPREX · COPAXONE · Cambia · DUOPA · Dhivy · Dynasplint · EMGALITY · Eprontia · Exablate · FARXIGA · FIRDAPSE · Fintepla · Fycompa · GAMMAGARD · GENERAL DBS · GOCOVRI · Gamunex-C · Glatiramer Acetate · Gocovri · HETLIOZ · Hetlioz · Hizentra · Horizant · I-STAT · INBRIJA · INFINITY · INGREZZA · KISUNLA · KYNMOBI · LEQEMBI · LINQ II · Leqembi · NAMZARIC · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Neupro · Nourianz · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONPATTRO · OXTELLAR XR · Ocrevus · Ocrevus Zunovo · Omnia · PANZYGA · PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A · POMPE - DISEASE · Ponvory · QULIPTA · RADICAVA · RELEXXII · REXULTI · RYTARY · Rystiggo · SCS IPGs · SOLIRIS · SPINRAZA · Senza Spinal Cord Stimulation System · TECFIDERA · TEGSEDI · TROKENDI XR · TYSABRI · UBRELVY · ULTOMIRIS · VALTOCO · VNS Therapy · VUMERITY · VYEPTI · VYVGART · Vimpat · XCOPRI · ZTLido · Zilbrysq
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a neurology specialist in La Mesa?
Compare neurologists in the La Mesa area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
176
Per 100K population
5.4
County median income
$102,285
Nearest hospital
GROSSMONT HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Bahreman is a clinical cardiology specialist, with above-average Medicare volume (top 23% in CA), with low-engagement industry engagement in the top 17% of CA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Bahreman experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Bahreman performed 444 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bahreman receive payments from pharmaceutical companies?
Yes. Dr. Bahreman received a total of $16,997 from 70 companies across 764 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bahreman's costs compare to other neurologists in La Mesa?
Dr. Bahreman's average Medicare payment per service is $158. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bahreman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →